Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001571049-14-001071
Filing Date
2014-04-07
Accepted
2014-04-07 16:59:56
Documents
6
Effectiveness Date
2014-04-07

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS t1400606_defa14a.htm DEFA14A 19539
2 GRAPHIC t1400606_pc1.jpg GRAPHIC 408233
3 GRAPHIC t1400606_pc2.jpg GRAPHIC 737848
4 GRAPHIC t1400606_pc3.jpg GRAPHIC 290838
5 GRAPHIC t1400606_pc4.jpg GRAPHIC 264916
6 GRAPHIC t1400606_pc5.jpg GRAPHIC 89396
  Complete submission text file 0001571049-14-001071.txt   2489330
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-50626 | Film No.: 14749210
SIC: 2834 Pharmaceutical Preparations